Kyowa Kirin
NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo
Phil Taylor
HEOR, Kyowa Kirin, lymphoma, NHS, NICE, Oncology, Poteligeo
0 Comment
Boost for AZ as Ultomiris gets CHMP nod for expanded label
Phil Taylor
Alexion, AstraZeneca, Kyowa Kirin, Nexviadyme, Nouryant, Parkinson's disease, Pompe disease, rare disease, Sanofi Genzyme, Soliris, Ultomiris
0 Comment
Scotland backs rare blood cancer drug Poteligeo rejected by NICE
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Calquence, Eli Lilly, Kyowa Kirin, NHS, nintedanib, Olumiant, Oncology, Poteligeo, Scotland, Scottish Medicines Consortium, Servier
0 Comment
Amgen pays Kyowa $400m upfront for OX40 eczema drug
Phil Taylor
Amgen, atopic dermatitis, dermatology, Dupixent, Kyowa Kirin, licensing, OX40, Regeneron, Sanofi
0 Comment
Kyowa Kirin backs €125m life science fund closed by Fountain Healthcare
Phil Taylor
European biotech, financing, Fountain Healthcare, Kyowa Kirin, Life Sciences, venture capital
0 Comment
GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival
Richard Staines
anaemia, Astellas, AstraZeneca, chronic kidney disease, Duvroq, FibroGen, GlaxoSmithKline, Kyowa Kirin
0 Comment
FDA approves Kyowa Kirin’s new Parkinson’s drug Nourianz
Richard Staines
Kyowa Kirin, neurology, Parkinson's
0 Comment
Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?
Richard Staines
cancer, Kyowa Kirin, ophthalmology
0 Comment